GSK Pharma forays into gynaecological cancer treatment in India

GlaxoSmithKline Pharmaceuticals Ltd. stock zoomed as much as 2% on Monday, August 25. This movement in shares came after the company announced its entry into the oncology segment in India with Jemperli and Zejula therapies that can be used for the treatment of gynaecological cancers.

At around 2.14 PM, GSK Pharma was trading 0.28% higher at ₹2,806.70 per piece, against the previous close of ₹2,798.80 on NSE. The counter touched an intraday high and low of ₹2,869, and ₹2,797.50, respectively.

Jemperli is one and only approved programmed death receptor-1 (PD-1) immunotherapy. This will be used for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high advanced or recurrent endometrial cancer, in India.

This therapy blocks the PD-1 pathway. This is a mechanism that is used by cancer cells to evade immune detection, hence allowing immune cells to recognise and attack the tumor more effectively, informed the company in its filing with the bourses.

Additionally, Zejula is the only PARP (Poly(ADP-ribose) polymerase) inhibitor approved. This will be first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer in India, the company informed.

GSK also informed that it is planning to unveil a patient support programme for empowerment of patients to access these innovative therapies.

Related Posts

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

The National Pharmaceutical Pricing Authority (NPPA) has said that it is not mandatory for the oncology drug manufacturers who are revising the drug prices as per the recently announced Trade…

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

Mankind Pharma shares jumped nearly 8% on Tuesday to an intraday high of Rs 2,500 on the NSE after the company reported a 38% year-on-year rise in Q2 profit after…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

Yashoda Medicity: Baby takes a Giant Step in just One Year

Yashoda Medicity: Baby takes a Giant Step in just One Year

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

GLP-1 injections recalled across the US over sterility concerns

GLP-1 injections recalled across the US over sterility concerns

Govt allows third-party agencies to conduct departmental inspections

Govt allows third-party agencies to conduct departmental inspections

Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

Fridge-free vaccines could reach more people, but there are still practical challenges in African settings